Catalog No.
DHJ31004
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Mucin-16, CA-125, Ovarian carcinoma antigen CA125, CA125, MUC-16, Ovarian cancer-related tumor marker CA125, MUC16
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q8WXI7
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
DMUC5754A (conjugate), MMUC1206A (nonconjugate), CAS: 1615692-28-8
Clone ID
Sofituzumab
Sacituzumab Govitecan: First Approval, PMID: 32529410
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer, PMID: 30786188
Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer, PMID: 31398063
Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors, PMID: 31584574
Sacituzumab govitecan: an antibody-drug conjugate, PMID: 28503956
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy, PMID: 32301634
Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer, PMID: 33070624
Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan, PMID: 31208270
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer, PMID: 28291390
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer, PMID: 33168656
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial, PMID: 32946924
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer, PMID: 32223649
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors, PMID: 25944802
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers, PMID: 25915780
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics, PMID: 28558150
Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?, PMID: 30507322
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC), PMID: 26101915
Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer, PMID: 33196706
Antibodies to watch in 2020, PMID: 31847708
A closer look at sacituzumab govitecan-hziy, PMID: 33406063
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan, PMID: 28679770
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan, PMID: 28548889
Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan, PMID: 33089726
Sacituzumab govitecan-hziy for triple-negative breast cancer, PMID: 30827748
Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer, PMID: 31189048
Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan), PMID: 26106073
Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. Reply, PMID: 31189049
Antibody-drug conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan, PMID: 30822636
Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer, PMID: 33195736
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer, PMID: 33882206
Trop2: Jack of All Trades, Master of None, PMID: 33187148
Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas, PMID: 32082489
Novel antibody-drug conjugates for triple negative breast cancer, PMID: 32426047
Antibodies to watch in 2019, PMID: 30516432
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target, PMID: 29989029
Irinotecan: 25 years of cancer treatment, PMID: 31415916
Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo, PMID: 31891442
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan, PMID: 31969666
Sacituzumab govitecan (Trodelvy) for metastatic triple-negative breast cancer, PMID: 33757114
Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report, PMID: 29977989
The emerging role of antibody-drug conjugates in urothelial carcinoma, PMID: 32552213
Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review, PMID: 30931493
Antibody-Drug Conjugates in Urothelial Carcinomas, PMID: 32008109
Sacituzumab govitecan activity in advanced breast cancer, PMID: 28343977
Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer, PMID: 32117765
The evolving management of metastatic triple negative breast cancer, PMID: 32563561
Sacituzumab Govitecan in Metastatic Breast Cancer, PMID: 34260847
Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape, PMID: 34225076
Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities, PMID: 34176192
Major clinical research advances in gynecologic cancer in 2019, PMID: 32319232
For research use only. Not for human or drug use.
